Clopidogrel: A Case for Indication-Specific Pharmacogenetics
- 1 May 2012
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 91 (5) , 774-776
Abstract
The CYP2C19*2 loss‐of‐function allele is associated with reduced generation of active metabolites of clopidogrel. However, meta‐analyses have supported or discounted the impact of genotype on adverse...Keywords
This publication has 10 references indexed in Scilit:
- CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular EventsJAMA, 2011
- Pharmacogenomics and ClopidogrelJAMA, 2011
- Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysisBMJ, 2011
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel TherapyClinical Pharmacology & Therapeutics, 2011
- Effects ofCYP2C19Genotype on Outcomes of Clopidogrel TreatmentNew England Journal of Medicine, 2010
- Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCIJAMA, 2010
- Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor CoadministrationJACC, 2010
- Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel TherapyJAMA, 2009
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelNew England Journal of Medicine, 2009
- Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjectsBlood, 2006